U.S. Urinary Catheterization & CAUTI Landscape

Table of Contents

Chapter 1. CAUTI Market & Epidemiology in the U.S.
                    1.1. Correlation Between Catheterization and CAUTI Risk
                    1.2. Market Definitions
                    1.3. Population size estimates for each patient group
                    1.4. Prevalence of catheterization and typical duration of use
                    1.5. Types of catheter used & market share (%) & market size (USD Million)
                    1.6. U.S. State Wise Data Catheter-associated urinary tract infections, 2023
                    1.7. Prevention of CAUTI
                    1.8. Advancements in Antimicrobial Catheter Technologies
                        1.8.1. Silver Alloy Hydrogel-Coated Catheters (SAH)
                        1.8.2. Superhydrophobic Surfaces
                        1.8.3. Integration of Technology
                    1.9. CAUTI Incidence & Risk Factors
                        1.9.1. Prevalence of CAUTI in each patient segment
                        1.9.2. Correlation between catheterization duration and CAUTI risk
                        1.9.3. Bacterial profiles & antibiotic resistance trends
                    1.10. Treatment & Prevention Landscape
                        1.10.1. Current standard of care for CAUTI management
                        1.10.2. Use of antimicrobial catheters & infection control strategies
                        1.10.3. Antibiotic prescribing patterns for CAUTI
                    1.11. Clinical Burden and CAUTI Risk Across Age Groups
                    1.12. Economic & Clinical Impact of CAUTI
                        1.12.1. Hospitalization costs and length of stay due to CAUTI
                        1.12.2. Impact of catheterization on antibiotic resistance and antibiotic prescribing
                        1.12.3. Reimbursement challenges & payer coverage
                        1.12.4. Patient Groups With a Particularly High Clinical Unmet Need
                            1.12.4.1. Spinal Cord Injury
                            1.12.4.2. Spina Bifida
                            1.12.4.3. Cancer Therapy
                    1.13. Patients with Neurologic Bladder Dysfunction
                        1.13.1. Spinal Cord Injury (SCI)
                        1.13.2. Multiple Sclerosis (MS)
                        1.13.3. Stroke
                        1.13.4. Parkinson's Disease
                        1.13.5. Dementia
                        1.13.6. Congenital Neurologic Conditions (especially pediatric and adult spina bifida)
                    1.14. Patients with Chronic Urinary Retention
                        1.14.1. Benign Prostatic Hyperplasia (BPH)
                        1.14.2. Urethral strictures
                        1.14.3. Chronic retention unresponsive to treatment
                    1.15. Patients with Chronic Urinary Incontinence & Skin Integrity Issues
                        1.15.1. Severe incontinence refractory to other treatments
                        1.15.2. Skin wounds or pressure ulcers
                        1.15.3. High burden of care from incontinence
                        1.15.4. Patient preference for catheterization
                    1.16. Patients with Immobility
                        1.16.1. Severe mobility impairment
                        1.16.2. Extended critical illness patients
                    1.17. Terminally ill patients
                        1.17.1. Palliative care patients